Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, USA.
Urology. 2010 Mar;75(3):502-9. doi: 10.1016/j.urology.2009.05.099. Epub 2009 Dec 29.
The landmark Prostate Cancer Prevention Trial (PCPT) generated interest in the potential health benefits and cost of reducing prostate cancer risk--specifically, the potential role of 5alpha-reductase inhibitors. However, the PCPT raised several unanswered questions, including the cause and significance of the increased incidence of high-grade tumors associated with finasteride. In the present study, we review the PCPT findings and unanswered questions, next steps in this field, and ongoing prostate cancer prevention trials addressing these unanswered questions. Particular emphasis is placed on the design of the second large-scale trial of a 5alpha-reductase inhibitor, the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
标志性的前列腺癌预防试验（PCPT）引起了人们对降低前列腺癌风险的潜在健康益处和成本的兴趣，具体来说，就是 5α-还原酶抑制剂的潜在作用。然而，PCPT 提出了几个尚未回答的问题，包括与非那雄胺相关的高级别肿瘤发生率增加的原因和意义。在本研究中，我们回顾了 PCPT 的发现和未回答的问题、该领域的下一步措施以及正在进行的旨在解决这些未回答问题的前列腺癌预防试验。特别强调了第二次大规模 5α-还原酶抑制剂试验的设计，即 dutasteride 降低前列腺癌事件的研究（REDUCE 试验）。
